Dr Catherine Guette
Group Leader of the Clinical Proteomics Unit, Cancer Research Institution
Project goal
In colorectal and breast cancers, we use proteomics to identify a senescence secretome to find biomarkers that could predict the efficacy of treatments.
The solution
- The TripleTOF® 5600+ System, a robust LC-MS/MS platform working at high throughput in microflow mode. It’s way faster – 1 hour per sample - and more robust compared to nano flow with similar sensitivity.
- We use SWATH Acquisition to get comprehensive coverage and high quality quantitation across many samples.
Biggest Challenges Right Now
- Ability to identify and quantify as many proteins as possible in our samples
- Acquisition of reproducible quantitative data
- Creation of permanent digital record of the proteome for each sample
The outcomes
- We can work on very large cohorts (more than 150 tumor samples) to identify robust biomarkers or to better understand the cancer biology.
Type of organization
Cancer Research Institution, Biomarkers & Omics
Goals
Identification of soluble and detectable markers of tumor progression
SCIEX products/applications
- SWATH® Acquisition on the TripleTOF® 5600+ System
- SCIEX NanoLC™ 400 System (Microflow Mode)
- PeakView® Software
- MarkerView™ Software
- Multi-Omics Data Integration with OneOmics™